Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

(OP: LOBEF )

0.0172 +0.0012 (+7.50%)
Streaming Delayed Price Updated: 2:55 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about LOBEF

Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
Via Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
Lobe Sciences Ltd. (OTCQB: LOBEF), a biopharmaceutical company focused on non-hallucinatory doses of stabilized psychedelic-based compounds to treat rare diseases, has commenced its Phase 1 clinical... 
Via Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
Mass-Scale Psilocin Clinical Supplies Are Ready For Upcoming Trials
Canadian biotech company Lobe Sciences Ltd. 
Via Benzinga
New Share Consolidation of Lobe Sciences Ltd., Here's What Changes
Lobe Sciences Ltd. 
Via Benzinga
Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up
Orphan and rare diseases drug company Lobe Sciences Ltd. (OTCQB: LOBEF) is set to acquire Altemia & Company LLC. 
Via Benzinga
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
As early as the 1950s, scientists were researching the possible therapeutic benefits of psychedelics such as LSD and psilocybin mushrooms. 
Via Benzinga
Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic
Lobe Sciences (OTCQB: LOBEF), the psychedelics company performing drug R&D with sub-hallucinatory doses of psychedelics has signed a research agreement with headache medicine specialist Dr. Lauren R. 
Via Benzinga
Psychedelics Funding At Its Best: $1.5 M Destined To Psilocybin Clinical Trials In Australia
Psychedelics biopharma company Lobe Sciences Ltd. 
Via Benzinga
This Psychedelic Company Just Signed An Exclusive Deal For Psilocin Clinical Trials In Australia
Life sciences company Lobe Sciences Ltd. 
Via Benzinga
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
Mydecine (OTC: MYCOF) and Lobe Sciences (OTCQB: LOBEF), two companies in the psychedelics space, have filed patent applications. 
Via Benzinga
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.